421 related articles for article (PubMed ID: 29737600)
1. Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment.
Tanaka HY; Kano MR
Cancer Sci; 2018 Jul; 109(7):2085-2092. PubMed ID: 29737600
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Strategies to Overcome Fibrotic Barriers to Nanomedicine in the Pancreatic Tumor Microenvironment.
Tanaka HY; Nakazawa T; Enomoto A; Masamune A; Kano MR
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765684
[TBL] [Abstract][Full Text] [Related]
3. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
4. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer.
Meng H; Nel AE
Adv Drug Deliv Rev; 2018 May; 130():50-57. PubMed ID: 29958925
[TBL] [Abstract][Full Text] [Related]
5. From Passive Targeting to Personalized Nanomedicine: Multidimensional Insights on Nanoparticles' Interaction with the Tumor Microenvironment.
Sebak AA; El-Shenawy BM; El-Safy S; El-Shazly M
Curr Pharm Biotechnol; 2021; 22(11):1444-1465. PubMed ID: 33308126
[TBL] [Abstract][Full Text] [Related]
6. Stromal disruption facilitating invasion of a 'nano-arsenal' into the solid tumor.
Fu Y; Saraswat AL; Monpara J; Patel K
Drug Discov Today; 2022 Apr; 27(4):1132-1141. PubMed ID: 34823002
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer.
Lu T; Prakash J
Int J Nanomedicine; 2021; 16():6313-6328. PubMed ID: 34552327
[TBL] [Abstract][Full Text] [Related]
8. High-resolution 3D visualization of nanomedicine distribution in tumors.
Moss JI; Barjat H; Emmas SA; Strittmatter N; Maynard J; Goodwin RJA; Storm G; Lammers T; Puri S; Ashford MB; Barry ST
Theranostics; 2020; 10(2):880-897. PubMed ID: 31903157
[TBL] [Abstract][Full Text] [Related]
9. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer.
Ji T; Li S; Zhang Y; Lang J; Ding Y; Zhao X; Zhao R; Li Y; Shi J; Hao J; Zhao Y; Nie G
ACS Appl Mater Interfaces; 2016 Feb; 8(5):3438-45. PubMed ID: 26759926
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology.
Zhan HX; Zhou B; Cheng YG; Xu JW; Wang L; Zhang GY; Hu SY
Cancer Lett; 2017 Apr; 392():83-93. PubMed ID: 28189533
[TBL] [Abstract][Full Text] [Related]
12. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
[TBL] [Abstract][Full Text] [Related]
13. The new era of pancreatic cancer treatment: Application of nanotechnology breaking through bottlenecks.
Luo W; Zhang T
Cancer Lett; 2024 Jul; 594():216979. PubMed ID: 38795762
[TBL] [Abstract][Full Text] [Related]
14. Modulating the tumor microenvironment with new therapeutic nanoparticles: A promising paradigm for tumor treatment.
Zhang Y; Ho SH; Li B; Nie G; Li S
Med Res Rev; 2020 May; 40(3):1084-1102. PubMed ID: 31709590
[TBL] [Abstract][Full Text] [Related]
15. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer.
Vennin C; Murphy KJ; Morton JP; Cox TR; Pajic M; Timpson P
Gastroenterology; 2018 Mar; 154(4):820-838. PubMed ID: 29287624
[TBL] [Abstract][Full Text] [Related]
16. Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Neesse A; Bauer CA; Öhlund D; Lauth M; Buchholz M; Michl P; Tuveson DA; Gress TM
Gut; 2019 Jan; 68(1):159-171. PubMed ID: 30177543
[TBL] [Abstract][Full Text] [Related]
17. Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.
Kim J; Cho H; Lim DK; Joo MK; Kim K
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373227
[TBL] [Abstract][Full Text] [Related]
18. Antifibrotic Agent Mediated Tumor Microenvironment Modulation and Improved Nanomedicine Delivery in Solid Tumor.
Sandha KK; Behera C; Chibber P; Kumar R; Kumar A; Mondhe DM; Singh G; Gupta PN
Mol Pharm; 2023 Jun; 20(6):2927-2941. PubMed ID: 37194684
[TBL] [Abstract][Full Text] [Related]
19. Exploring the tumor microenvironment with nanoparticles.
Miao L; Huang L
Cancer Treat Res; 2015; 166():193-226. PubMed ID: 25895870
[TBL] [Abstract][Full Text] [Related]
20. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
